Group 1 - The core viewpoint of the article highlights the performance of the 中证2000ETF嘉实 (159535), which opened with a decline of 0.45% at 1.337 yuan [1] - The fund's performance benchmark is the 中证2000 index return, managed by 嘉实基金管理有限公司, with a return of 34.32% since its establishment on September 14, 2023, and an 8.90% return over the past month [1] Group 2 - The top holdings of 中证2000ETF嘉实 (159535) include stocks such as 每日互动, 汉威科技, 宏创控股, 东土科技, 恒宝股份, 台基股份, 热景生物, 仕佳光子, 泰恩康, and 益方生物, with varying performance on the opening day [1] - Specific stock performances on the opening day include 每日互动 down 0.72%, 汉威科技 down 0.02%, 宏创控股 up 0.06%, 东土科技 up 0.31%, 恒宝股份 down 0.54%, 台基股份 up 0.44%, 热景生物 down 0.75%, 仕佳光子 down 0.81%, 泰恩康 up 0.03%, and 益方生物 down 1.86% [1]

Core Viewpoint - China's innovative pharmaceuticals have transitioned from being followers to key players in global medical innovation, achieving significant breakthroughs in core treatment areas such as metabolic diseases and oncology, with a surge in new drug approvals and international progress [1][3]. Group 1: Market Trends - The attention of A-share investors towards innovative pharmaceuticals has significantly increased this year, with numerous companies actively disclosing their R&D and clinical progress [2]. - The total value of license-out transactions for innovative drugs in China is projected to exceed $60 billion by mid-2025, surpassing the total for 2024, with 16 transactions exceeding $1 billion each [3]. - The market size of China's innovative drugs reached 679 billion yuan in 2022, expected to exceed 1 trillion yuan by 2026 and reach 1.12 trillion yuan by 2027 [6]. Group 2: International Expansion - Chinese innovative drug companies are accelerating their international business, with 81 companies generating over 100 billion yuan in overseas revenue from 2022 to 2024, accounting for more than 14% of their total revenue [7]. - The proportion of China's innovative drug transactions in the global market has increased from 10.8% in 2015 to approximately 52.5% by August 2023 [6]. Group 3: Policy and Financial Support - The Chinese government has implemented policies to support the high-quality development of innovative drugs, significantly reducing the time from drug approval to inclusion in the medical insurance directory from about 5 years to approximately 1 year [8]. - From 2015 to 2024, the financing in China's innovative drug sector exceeded 1.23 trillion yuan, providing strong momentum for industry growth [9]. Group 4: R&D Investment - The number of companies in the pharmaceutical and biotechnology sector has increased from over 220 in 2015 to nearly 500 currently, with R&D investment in the sector exceeding 140 billion yuan in 2024, a fivefold increase since 2015 [9]. - Among the 81 innovative drug companies, R&D investment rose from approximately 8.8 billion yuan in 2015 to over 57.8 billion yuan in 2024, with R&D intensity increasing from 3.29% to 8.04% [9]. Group 5: Company Developments - Companies such as Betta Pharmaceuticals and Rundu Co. have reported significant advancements in their innovative drug pipelines, with Betta's drug expected to be approved by June 2025 and Rundu's drug completing phase III clinical trials [12]. - The stock performance of companies involved in innovative drugs has surged, with some companies experiencing average increases of over 50% since May 1, 2023 [13]. Group 6: Institutional Interest - 13 companies have received significant institutional interest this year, with some experiencing over 30% increase in financing, indicating strong market confidence in innovative drug investments [14]. - Companies like BeiGene and TaiGen Biotechnology are projected to see substantial profit growth in 2025 and 2026, with BeiGene potentially turning profitable this year [15].

Core Insights - The forum focused on innovative immunotherapy and clinical translation opportunities, attracting over a hundred participants from various sectors [2] - The clinical trial results for CKBA, an innovative drug for vitiligo, showed a 36% efficacy rate and good safety, particularly in children [2][4] - CKBA is positioned to fill a significant gap in the treatment of pediatric vitiligo, as there are currently no approved drugs for this age group [5] Group 1: Clinical Development - CKBA has completed Phase II clinical trials for vitiligo, with 18 out of 50 patients showing improvement and an adverse reaction rate of only 18% [4] - The drug is expected to enhance the efficacy of phototherapy while reducing side effects, providing a new strategy for combined treatment [4] - The company has submitted a breakthrough therapy designation application to the National Medical Products Administration (NMPA) and is advancing to Phase III trials [7] Group 2: Market Opportunity - The global prevalence of vitiligo is approximately 1% to 3%, with a significant portion of patients being children aged 2 to 12, indicating a high unmet medical need [3] - Current treatments in China lack effective targeted therapies, primarily relying on topical corticosteroids and other medications that have limited efficacy and potential side effects [3] - The domestic vitiligo treatment market is seen as a promising area for potential blockbuster products, with a large patient base and urgent demand [6] Group 3: Innovation and Strategy - The company is committed to innovation as a core driver of growth, with R&D investments exceeding 20% of revenue in 2023 and 2024 [6] - CKBA represents a shift in research focus from psoriasis to vitiligo, driven by the significant clinical needs in the latter [3][6] - The company aims to submit a new drug application for CKBA for both adult and pediatric vitiligo by 2027 [7]

Group 1: Pet Industry Insights - The pet consumption market in urban areas is continuously growing due to rising living standards and increasing emotional companionship needs, leading to a shift from basic survival consumption to quality and personalized consumption [1] - The market concentration in China's pet industry remains low, but as consumer awareness of pet food deepens, market share is expected to gradually concentrate towards leading brands [1][4] - Zhongchong Co., Ltd. reported a revenue of 2.432 billion yuan for the first half of 2025, a year-on-year increase of 24.32%, with a net profit of 203 million yuan, up 42.56% [4] Group 2: High-end Equipment Manufacturing - Jerry Co., Ltd. reported a revenue of 6.9 billion yuan for the first half of 2025, reflecting a nearly 40% year-on-year growth [1] - The company emphasized its international strategy, with overseas business revenue accounting for a growing proportion of total income, reaching 3.295 billion yuan in the first half of 2025, a year-on-year increase of 38.38% [1] - New orders from overseas markets increased by 24.16% year-on-year, indicating strong demand and successful international expansion [1] Group 3: Innovative Pharmaceutical Sector - The innovative drug sector has seen a continuous rise this year, with Taiankang's subsidiary completing Phase II clinical trials for its innovative drug CKBA ointment, showing positive efficacy and safety [2] - The company plans to submit research data for breakthrough therapy application and registration clinical communication to the National Medical Products Administration [2] - Jiuzhou Pharmaceutical reported improved capacity utilization compared to the first quarter, with a positive outlook for the innovative drug industry driven by better financing conditions and active business development transactions [2]

Market Performance - On August 8, A-shares' three major indices collectively closed lower, with the Shanghai Composite Index down 0.12% at 3635.13 points, the Shenzhen Component Index down 0.26% at 11128.67 points, and the ChiNext Index down 0.38% at 2333.96 points [1] Fund Manager Changes - In the past 30 days (July 9 to August 8), a total of 477 fund products experienced changes in fund managers, with 29 fund products announcing manager departures on August 8 alone [3] - The reasons for the changes include three managers leaving due to job changes, two due to personal reasons, and three due to product expiration [3] Fund Manager Details - Notable fund manager departures include Wang Gang from the招商丰泽混合A fund, which has an asset scale of 6.385 billion yuan and achieved a return of 71.45% over 8 years and 13 days [4] - New fund managers include Zhao Ming, who started managing 中海合嘉增强收益债券A and C funds, and Ren Dongxuan, who took over 嘉合锦荣混合C and 蒸合棉束温合A funds [6][5] Fund Company Research Activity - In the past month, 博时基金 conducted the most company research, engaging with 56 listed companies, followed closely by 富国基金 and 华夏基金, each with 51 companies [7] - The most researched industry was communication equipment, with 307 instances, followed by specialized equipment with 246 instances [7] Individual Stock Research - 德福科技 was the most researched stock in the past month, with 79 fund management companies participating in the research, followed by 中际旭创 and 中宠股份 with 75 and 71 respectively [9] - In the past week (August 1 to August 8), 中宠股份 was the most researched stock, receiving attention from 71 fund institutions [8]

市场表现上，基金调研股中，近5日上涨的有5只，涨幅居前的有威尔高、优宁维、科士达等，涨幅为 5.59%、2.10%、1.54%；下跌的有1只，跌幅居前的有中旗新材等，跌幅为4.35%。 业绩方面，基金调研公司中，公布上半年业绩预告的共有2家，业绩预告类型来看，预增有1只。以净利 润增幅中值来看，净利润增幅最高的是威尔高，预计净利润中值为4650.00万元，同比增幅为21.71%。 （数据宝） 8月4日基金调研公司一览 昨日基金共对6家公司进行调研，扎堆调研东威科技、泰恩康等。 证券时报·数据宝统计，8月4日共8家公司被机构调研，按调研机构类型看，基金参与6家公司的调研活 动。东威科技最受关注，参与调研的基金达59家；泰恩康、威尔高等分别获38家、3家基金集体调研。 基金参与调研的公司中，按所属板块统计，深市主板公司有2家，创业板公司有3家，科创板公司有1 家。 从基金调研公司的A股总市值统计，总市值不足100亿元的有3家，分别是优宁维、威尔高、中旗新材 等。 | 代码 | 简称 | 基金家数 | 最新收盘价（元） | 近5日涨跌幅（%） | 行业 | | --- | --- | --- | --- | --- ...

Summary of Conference Call on CKBA Clinical Phase II Data Company and Industry - **Company**: CKBA - **Industry**: Pharmaceutical, specifically focusing on dermatological treatments and neurodegenerative diseases Key Points and Arguments Clinical Trial Results - CKBA demonstrated a differentiated advantage in treating vitiligo by inhibiting tissue-resident memory T cell binding and reducing reactive oxygen species (ROS) in melanocytes, achieving both immune modulation and melanin production [1][7] - The Phase II clinical trial results indicated that facial vitiligo treatment was more effective than neck treatment, attributed to greater natural light exposure promoting melanocyte differentiation and secretion [1][12] - In the high-quality group, the improvement rate for facial skin color reached 50%, significantly higher than the 18% in the MG group [1][16] Future Clinical Plans - The company plans to initiate Phase III clinical trials by the end of the year, focusing on facial efficacy and expanding the sample size to include patients aged 12-65 [1][2] - A breakthrough therapy application will be submitted soon to support the Phase III trial [2] Safety and Efficacy - CKBA's adverse event rate is only 18%, significantly lower than the 60% rate associated with traditional treatments like Jak inhibitors, making it suitable for long-term maintenance therapy, especially for children aged 2-12 [1][7][19] - The drug is expected to be the first treatment specifically for vitiligo in children aged 2-12 globally, addressing a strong demand in China where there are approximately 12 million such patients [3][18] Pricing Strategy - The annual treatment cost for CKBA is estimated to be around 10,000 to 20,000 yuan, significantly lower than the 150,000 yuan for traditional treatments, enhancing drug accessibility [3][8] Other Research Initiatives - NKBA, a high bioavailability derivative of AKBA, has initiated preclinical studies for Alzheimer's disease and anti-aging, with IND submission expected in Q3 next year [1][5] - The company has submitted a Phase II clinical application for rosacea and plans to start clinical trials shortly, with a treatment cycle of about three months [1][6] Market Position and Competitive Advantage - CKBA's unique mechanism of action and safety profile position it favorably against existing treatments, making it particularly appealing for long-term use in pediatric patients [1][7][19] - The company aims to conduct head-to-head comparisons with existing treatments like Ruxolitinib once it is approved, to establish a clear safety and efficacy advantage [18] Clinical Management Challenges - The management of clinical trials for vitiligo is complex due to long cycles and the need for placebo controls, but the company is confident in improving data collection and trial management in Phase III [15] Conclusion - CKBA is poised to make significant advancements in the treatment of vitiligo, particularly in pediatric populations, with a strong focus on safety, efficacy, and affordability, while also exploring new therapeutic avenues in neurodegenerative diseases.

中证报中证网讯(王珞)8月4日，泰恩康（301263）发布两项重大战略进展公告。公司控股子公司江苏博 创园生物医药科技有限公司自主研发的1类创新药CKBA软膏治疗非节段型白癜风的II期临床试验取得突 破性成果，高剂量组疾病好转及复色比例达36%，达到试验主要终点。同日，公司宣布推出总规模达2 亿元的2025年员工持股计划，覆盖不超过150名核心骨干，以长效激励机制护航创新研发。 全球首创新药拟申报突破性疗法 根据临床试验数据，这项由杭州市第三人民医院皮肤病研究所所长许爱娥教授领衔、全国21家医疗中心 共同参与的II期研究显示：接受1.5%BID高剂量CKBA软膏治疗的患者中，36%实现疾病好转及不同程 度复色，在面颈部白癜风评分指数(F-VASI50和F-VASI25)改善比例上显著优于安慰剂组。药物安全性表 现突出，相关不良事件发生率仅为18%，主要表现为轻度瘙痒和红斑，未报告严重不良事件或系统性不 良反应。 CKBA软膏作为全球首创(First-in-Class)非免疫抑制剂小分子药物，其创新机制直击临床痛点——通过靶 向T细胞脂肪酸代谢通路发挥作用。研究团队强调，白癜风患者需持续用药2年以上才能显著降低 ...

Market Strategy - The market is experiencing a volume contraction rebound, with the military industry sector showing strong performance [5][6] - The overall A-share market saw a rise of 0.76%, with the Shanghai Composite Index up by 0.66% and the Sci-Tech 50 Index up by 1.22% [6][7] - The military industry, machinery equipment, and non-ferrous metals sectors performed well, while social services, oil and petrochemicals, and retail sectors lagged behind [7] Company Performance - **Ninebot Company (689009.SH)** reported a 2025 semi-annual net profit increase of 108.45%, with total revenue of 11.742 billion yuan, up 76.14% year-on-year [23][24] - **Yingzi Network (688475.SH)** achieved a net profit growth of 7.38% in the first half of 2025, with total revenue of 2.827 billion yuan, reflecting a 9.45% increase [26][27] - **Taincon (301263.SZ)** announced positive preliminary results for its CKBA ointment in phase II clinical trials for vitiligo, meeting expected targets [29][30] - **Cangge Mining (000408.SZ)** reported a significant profit increase due to the performance of the Jilong Copper Mine, with total revenue of 1.678 billion yuan and a net profit of 1.8 billion yuan [32][34] Economic Dynamics - The actual use of foreign capital in Hunan Province reached 420 million USD in the first half of 2025, marking a 23% year-on-year increase, significantly higher than the national average [37][38]

三、公司审议本员工持股计划相关议案的决策程序合法、有效。本员工持股 计划遵循公司自主决定、员工自愿参加的原则，公司实施本员工持股计划前，通 过职工代表大会等方式，充分征求员工意见，不存在摊派、强行分配等方式强制 员工参与本员工持股计划的情形。 广东泰恩康医药股份有限公司 董事会薪酬与考核委员会关于公司 2025 年员工持股计划 相关事项的核查意见 广东泰恩康医药股份有限公司（以下简称"公司"）董事会薪酬与考核委员 会根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和 国证券法》（以下简称"《证券法》"）《关于上市公司实施员工持股计划试点 的指导意见》（以下简称"《指导意见》"）《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》（以下简称"《自律监管指引第 2 号》"）等法律、法规、规章和规范性文件，以及《广东泰恩康医药股份有限公 司章程》（以下简称"《公司章程》"）的规定，对公司 2025 年员工持股计划 （以下简称"本员工持股计划"）相关事项进行了核查，并发表核查意见如下： 一、公司不存在《指导意见》《自律监管指引第 2 号》等法律、法规、规章 和规范性文件所禁止 ...